Idiopathic pulmonary fibrosis trials in Belgium

In Belgium 12 Also abroad 111

12 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Where
Leuven, Liège, Sint-Lambrechts-Woluwe, Yvoir
Age
40 years and over
People
324 worldwide
Run by
Contineum Therapeutics
See details and how to joinNCT07284459 · EU 2025-521901-42-00
Phase 2Not yet taking people in Belgium
A Study to Test Whether BI 3810477 Helps People With Idiopathic Pulmonary Fibrosis When Taken With or Without Standard Treatment
Where
Liège
Age
40 years and over
People
70 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07926321 · EU 2026-527098-13-00
Phase 2Not yet taking people in Belgium
A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis
Where
Anderlecht, Leuven, Liège, Roeselare, Sint-Lambrechts-Woluwe
Age
18 years and over
People
112 worldwide
Run by
Agomab Spain S.L.U.
See details and how to join2026-526404-71-00 · EU 2026-526404-71-00
Phase 3Not yet taking people in Belgium
Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
Where
Kortrijk, Leuven, Liège, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years and over
People
2,380 worldwide
Run by
Bristol-Myers Squibb
See details and how to joinNCT07441408 · EU 2025-522373-10-00
Phase 3Taking people
Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Where
Antwerp, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
40 years and over
People
1,100 worldwide
Run by
PureTech
See details and how to joinNCT07284602 · EU 2025-524493-42-00
Phase 3Enrolling by invitation
Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
Where
Aalst, Anderlecht, Antwerp, Brussels, Leuven, Liège, Yvoir
Age
40 years and over
People
1,850 worldwide
Run by
United Therapeutics
See details and how to joinNCT04905693
Phase 2Taking people
Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases
Where
Brussels
Age
18 years and over
People
70
Run by
Erasme University Hospital
See details and how to joinNCT06189820
Phase 2Taking people
A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis
Where
Aalst, Leuven, Liège, Roeselare, Sint-Lambrechts-Woluwe, Yvoir
Age
40 years and over
People
240 worldwide
Run by
Chiesi Farmaceutici S.p.A.
See details and how to joinNCT07516951 · EU 2024-514246-37-00
Phase 2Taking people
An Open-Label Extension Study of Subjects who Received an Avalyn Inhaled Antifibrotic Agent
Where
Leuven, Liège
Age
18 years and over
People
128 worldwide
Run by
Avalyn Pharma Inc.
See details and how to join2024-518289-28-00 · EU 2024-518289-28-00
Phase 3Taking people
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis
Where
Kortrijk, Leuven, Liège, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years and over
People
239 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2023-503697-21-01 · EU 2023-503697-21-01
Phase 3Taking people
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis
Where
Kortrijk, Leuven, Liège, Sint-Lambrechts-Woluwe, Yvoir
Age
18 years and over
People
249 worldwide
Run by
Bristol-Myers Squibb Services Unlimited Company
See details and how to join2023-503699-25-00 · EU 2023-503699-25-00
Phase 3Taking people
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
Where
Aalst, Anderlecht, Antwerp, Edegem, Gent, Leuven, Liège, Sint-Lambrechts-Woluwe
Age
18 years and over
People
698 worldwide
Run by
United Therapeutics
See details and how to joinNCT05943535 · EU 2023-504904-26-00